Conceivably, as has been further demonstrated for another TKI-resistant CML cell line [139], SHP1 was downregulated in a cohort of CML patients that failed IM treatment. This evidence concerns the gene PTPN6 and chronic myelogenous leukemia, BCR-ABL1 positive.